Related references
Note: Only part of the references are listed.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CIVIL Working Party experience after a 7-year follow-up
Francesca Palandri et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome
Francesca Palandri et al.
HAEMATOLOGICA (2008)
Imatinib therapy for chronic myeloid leukemia: Where do we go now?
Jorge E. Cortes
JOURNAL OF CLINICAL ONCOLOGY (2008)
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
C. M. Lucas et al.
LEUKEMIA (2008)
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia
L Roy et al.
LEUKEMIA (2005)
Regression models for relative survival
PW Dickman et al.
STATISTICS IN MEDICINE (2004)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
EA Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
